URGN - Company ID 0001668243
UroGen Pharma Ltd. trades as URGN and has a market capitalization of $1.94 B, making it the #2165 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $109.79M, up 21.4% from the prior year and net income of -$153.49M. This page tracks UroGen Pharma Ltd. through 548 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years UroGen Pharma Ltd.'s revenue grew from $17.53M to $109.79M, a compound annual growth rate of 22.6%. Net profit margin compressed from -11.1% to -139.8% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-27 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-11 |
| Insider sale notice | 144 | 2026-05-08 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Proxy statement | DEF 14A | 2026-04-30 |
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution | UroGen Pharma, Ltd
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference | UroGen Pharma, Ltd
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC | UroGen Pharma, Ltd
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial | UroGen Pharma, Ltd
UroGen Pharma to Present at Upcoming Investor Conferences | UroGen Pharma, Ltd
The largest companies sharing UroGen Pharma Ltd.'s SEC industry classification (pharmaceutical preparations).
UroGen Pharma Ltd. (URGN) has a market capitalization of $1.94 B as of 2026-07-09, ranking #2165 among US-listed companies.
UroGen Pharma Ltd. reported revenue of $109.79M for fiscal year 2025, an increase of 21.4% year over year.
In its latest fiscal year UroGen Pharma Ltd. reported a net loss of $153.49M.